ARUP believes the FDA’s plan to regulate lab-developed tests will limit access to testing, increase costs, and face a court challenge, and is calling for collaboration to better address LDT oversight.
ARUP has gained a Conformité Européenne (CE) mark for AAV5 DetectCDx™ single-site use. The test will aid in determining the eligibility of non-U.S. patients for a new hemophilia A gene therapy.
A platform clients use to reduce testing waste, lower cost per test, and improve patient safety has won the prestigious Choosing Wisely Champion Award from the American Society for Clinical Pathology.
New ARUP Institute for Research and Innovation in Diagnostic and Precision Medicine™ will improve patient lives by advancing groundbreaking diagnostic and prognostic technologies.
The FDA now recommends the same assessment questions for all donors, regardless of gender or sexual orientation. ARUP Blood Services is one of the first donor centers to update processes in response.
ARUP Laboratories has received FDA approval for its companion diagnostic immunoassay, AAV5 DetectCDx™, which helps determine patient eligibility for a new gene therapy for severe hemophilia A.
ARUP and Gestalt Diagnostics announced a partnership under which ARUP will adopt Gestalt’s PathFlow® platform as a foundation for future digital pathology initiatives.
Efforts to train more medical laboratory scientists have been greatly boosted by $3 million in federal funds for a clinical lab training center that ARUP will build with the University of Utah.
The U.S. Food and Drug Administration (FDA) has updated its guidelines to allow individuals who lived or worked in the United Kingdom, France, or Ireland to donate blood and platelets.
ARUP’s culture of caring has earned it Utah Business magazine’s Best Companies To Work For Award for a fifth consecutive year.